Targeted heterologous antigen presentation on calicivirus virus-like particles
AssigneeTakeda Vaccines, Inc.
InventorsBryan Steadman, Ross Taylor
Life of this patent
Estimating the term…
Abstract
The present invention provides particle-forming chimeric proteins comprising a Calicivirus capsid protein and one or more heterologous antigen sequences. In particular, the present invention discloses engineered Calicivirus capsid protein sequences containing heterologous epitopes fused at internal locations such that the modified capsid proteins retain the ability to form virus-like particles when expressed in host cells. Virus-like particles comprising the chimeric proteins and vaccine formulations are also described.
Claims26
A chimeric protein comprising a Norovirus capsid protein having a P2 domain and at least one heterologous antigen or fragment thereof, wherein said at least one heterologous antigen or fragment thereof is inserted into said P2 domain of said capsid protein, and wherein the heterologous antigen or fragment thereof is not from any calicivirus said chimeric protein is capable of forming virus-like particles when expressed in a host cell.
Dependencies are inferred from the claim text.